CALR

T. Klampfl, H. Gisslinger, A. S. Harutyunyan, H. Nivarthi, E. Rumi, J. D. Milosevic

Somatic Mutations of Calreticulin in Myeloproliferative Neoplasm

The New England Journal of Medicine 2013, 1-12

J. Nangalia, C. E. Massie, E. J. Baxter, F. L. Nice, G. Gundem, D.C. Wedge

Somatic CALR Mutations in Myeloproliferative Neoplasm with Nonmutated JAK2

The New England Journal of Medicine 2013 , 1-14

G. Rotunno, C. Mannarelli, P. Guglielmelli, A. Pacilli, A. Pancrazzi, L. Pieri

Impact of calreticulin mutations on clinical and hematological phenotype and outcome in essential thrombocythemia

Blood 2014; 123(10): 1552-1555

E. Rumi, D. Pietra, V. Ferretti, T. Klampfl, A. S. Harutyunyan

JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes

Blood 2014; 123(10): 1544-1551

E. Rumi, D. Pietra, C. Pascutto, P. Guglielmelli, A. Martínez-Trillos

Clinical effect of driver mutations of JAK2, CALR, or MPL in primary myelofibrosis 

Blood 2014; 124(7): 1062-1069

A. Tefferi, P. Guglielmelli, D. R. Larson, Ch. Finke, E. A. Wassie

Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis 

Blood 2014; 124(16): 2507-2513